|
|
|
|
|
|
|
Soligenix Inc. (SNGX)
|
|
1.27 0.07 (5.83%)
|
10-19 16:00
|
|
Open:
|
1.35
|
Pre. Close:
|
1.2
|
|
High:
|
1.369
|
Low:
|
1.21
|
|
Volume:
|
305,042
|
Market Cap:
|
22M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
1.372 - 1.377
|
1.377 - 1.383
|
|
Low:
|
1.198 - 1.203
|
1.203 - 1.208
|
|
Close:
|
1.261 - 1.27
|
1.27 - 1.278
|
|
|
|
Technical analysis (as of: 2018-10-19 4:39:21 PM)
|
|
Overall:
|
|
|
Stoxline posted a NEUTRAL today, same as yesterday. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next Buy or SELL signal.
|
|
Target:
|
Six months: 2.05 One year: 2.57
|
|
Support:
|
Support1: 1.03 Support2: 0.86
|
|
Resistance:
|
Resistance1:
1.75 Resistance2: 2.20
|
|
Pivot:
|
1.57 
|
|
Moving Averages:
|
MA(5): 1.15 MA(20): 1.61
MA(100): 1.40 MA(250): 1.75
|
|
MACD:
|
MACD(12,26):
-0.11 Signal(12,26,9): -0.03
|
|
%K %D:
|
%K(14,3): 13.11  %D(3): 9.21
|
|
RSI:
|
RSI(14): 41.20
|
|
52-Week:
|
High: 3.7
Low: 0.91 Change(%): -38.3
|
|
Average Vol(K):
|
3-Month: 34217
10-Days 38545
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.SNGX has closed above bottom band by 28.9%. Bollinger Bands are 235% wider than normal. The large width of the bands suggest high volatility as compared to SNGX's normal range. The bands have been in this wide range for 16 bars. This is a sign that the current trend might continue.
|
|
|
Headline News
|
|
2018-10-15T12:38:14-04:00
Midday Gainers / Losers (10/15/2018)
2018-10-15T06:40:24-04:00
Soligenix to increase enrollment in late-stage study of SGX301 in CTCL
2018-10-15T06:00:00-04:00
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
